Stéphane Bancel, Moderna CEO (Tom Williams/CQ Roll Call via AP Images)
August 3, 2023 07:26 AM EDTUpdated 12:38 PM
Pharma

Up­dat­ed: Mod­er­na ramps up R&D spend in RSV, flu and cy­tomegalovirus in Q2

Zachary Brennan

Senior Editor

When com­pared to the same quar­ter last year, R&D ex­pens­es at the mR­NA pow­er­house Mod­er­na rose by 62% to $1.1 bil­lion in this lat­est quar­ter as the com­pa­ny stares down the po­ten­tial for sev­er­al new com­mer­cial prod­ucts.

The growth in R&D spend was large­ly due to more clin­i­cal tri­al-re­lat­ed ex­pens­es, the com­pa­ny said ahead of its quar­ter­ly earn­ings call on Thurs­day, for vac­cines in de­vel­op­ment for RSV as well as its sea­son­al flu and cy­tomegalovirus can­di­dates.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Spark co-founder launch­es new CNS gene ther­a­py biotech with $54M

No­var­tis makes a $1B ra­dio­phar­ma deal, buy­ing Mar­i­ana On­col­o­gy

Mod­er­na sticks to long-term strat­e­gy in first-quar­ter up­date, ends pact with Metageno­mi

Bridge­Bio spins out on­col­o­gy unit with $200M in back­ing for RAS as­sets

FDA asks for more da­ta on Dupix­ent in COPD in move that could de­lay a de­ci­sion

sponsored

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

A service from the Financial Times